重视肝肾综合征的基础和临床研究

李妍; 陆伦根

doi:10.3969/j.issn.1001-5256.2020.11.001

重视肝肾综合征的基础和临床研究

DOI: 10.3969/j.issn.1001-5256.2020.11.001

李妍,
陆伦根

上海交通大学附属第一人民医院消化科

详细信息

中图分类号: R575.2;R692
计量
- 文章访问数: 4853
- HTML全文浏览量: 30
- PDF下载量: 216
- 被引次数: 0
出版历程
- 收稿日期: 2020-07-27
- 出版日期: 2020-11-20

Emphasis on the basic and clinical research on hepatorenal syndrome

LI Yan,
LU LunGen

Department of Gastroenterology,Shanghai General Hospital,Shanghai Jiao Tong University

摘要

摘要:
肝肾综合征是失代偿期肝硬化最严重的并发症之一。晚期肝硬化患者内脏动脉血管扩张,并发肝硬化性心肌病时心输出量也减少,导致有效循环血容量减少、内源性血管收缩系统激活,肾脏血管明显收缩;兼之肾脏血流的自身调节受损,最终导致肾血流量和肾小球滤过率明显下降。全身炎症反应在肝肾综合征发病过程中也起着重要作用。肝肾综合征一经诊断应积极治疗。既往认为肝肾综合征是"功能性"肾功能不全,目前更倾向于肝肾综合征是从功能性肾功能不全到不同程度肾脏器质性改变逐步演进的一系列疾病谱。由于缺乏理想的肝肾综合征动物模型,目前对肝肾综合征病理生理学机制的探究和药理研究主要依赖临床研究,这给深入探究肝肾综合征自然史和病理生理学机制带来一定困难。主要结合近年来肝肾综合征的基础和临床研究进展及难点问题进行了讨论。
- 肝肾综合征 /
- 全身炎症反应综合征 /
- 肾上腺功能减退 /
- 治疗学
Abstract:
Hepatorenal syndrome( HRS) is one of the most severe complications of decompensated cirrhosis. Splanchnic arterial vasodilation in patients with advanced liver cirrhosis and the reduction in cardiac output due to cirrhotic cardiomyopathy may trigger the reduction in effective circulating blood volume,the activation of endogenous vasoconstrictor systems,and significant contraction of renal blood vessels;meanwhile,impairment in renal autoregulation of blood flow may finally lead to the reductions in renal blood flow and glomerular filtration rate. Systemic inflammation also plays an important role in the pathogenesis of HRS. The treatment of HRS should start as soon as it is diagnosed. In the past,HRS was considered“functional”renal insufficiency,while at present,it is considered a spectrum of diseases gradually changing from functional renal insufficiency to varying degrees of parenchymal damage. As there are still no suitable animal models of HRS,current investigations of the pathophysiology of HRS and related pharmacological research mainly rely on clinical studies,which brings difficulties in further understanding the natural history and pathophysiology of HRS. This article reviews the recent advances in the basic and clinical research on HRS and related difficulties.
- hepatorenal syndrome /
- systemic inflammatory response syndrome /
- adrenal insufficiency /
- therapeutics

HTML全文

参考文献(35)

[1] MINDIKOGLU AL,PAPPAS SC. New developments in hepatorenal syndrome[J]. Clin Gastroenterol Hepatol,2018,16(2):162-177. e1.

[2] ANGELI P,GINES P,WONG F,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. Gut,2015,64(4):531-537.

[3] ZHANG J,ROSSLE M,ZHOU X,et al. Terlipressin for the treatment of hepatorenal syndrome:An overview of current evidence[J]. Curr Med Res Opin,2019,35(5):859-868.

[4] ANGELI P,MORANDO F. Optimal management of hepatorenal syndrome in patients with cirrhosis[J]. Hepat Med,2010,2:87-98.

[5] SCHRIER RW,ARROYO V,BERNARDI M,et al. Peripheral arterial vasodilation hypothesis:A proposal for the initiation of renal sodium and water retention in cirrhosis[J]. Hepatology,1988,8(5):1151-1157.

[6] GINES P,SOLAE,ANGELI P,et al. Hepatorenal syndrome[J]. Nat Rev Dis Primers,2018,4(1):23.

[7] WONG F. Cirrhotic cardiomyopathy[J]. Hepatol Int,2009,3(1):294-304.

[8] KAZORY A,RONCO C. Hepatorenal syndrome or hepatocardiorenal syndrome:Revisiting basic concepts in view of emerging data[J]. Cardiorenal Med,2019,9(1):1-7.

[9] RUIZ-DEL-ARBOL L,MONESCILLO A,AROCENA C,et al. Circulatory function and hepatorenal syndrome in cirrhosis[J]. Hepatology,2005,42(2):439-447.

[10] AMIN AA,ALABSAWY EI,JALAN R,et al. Epidemiology,pathophysiology,and management of hepatorenal syndrome[J]. Semin Nephrol,2019,39(1):17-30.

[11] WONG F,MOORE K,DINGEMANSE J,et al. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome[J]. Hepatology,2008,47(1):160-168.

[12] ELIA C,GRAUPERA I,BARRETO R,et al. Severe acute kidney injury associated with non-steroidal anti-inflammatory drugs in cirrhosis:A case-control study[J]. J Hepatol,2015,63(3):593-600.

[13] European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites,spontaneous bacterial peritonitis,and hepatorenal syndrome in cirrhosis[J]. J Hepatol,2010,53(3):397-417.

[14] BERNARDI M,MOREAU R,ANGELI P,et al. Mechanisms of decompensation and organ failure in cirrhosis:From peripheral arterial vasodilation to systemic inflammation hypothesis[J]. J Hepatol,2015,63(5):1272-1284.

[15] KIM G,HUH JH,LEE KJ,et al. Relative adrenal insufficiency in patients with cirrhosis:A systematic review and Meta-analysis[J]. Dig Dis Sci,2017,62(4):1067-1079.

[16] ACEVEDO J,FERNANDEZ J,PRADO V,et al. Relative adrenal insufficiency in decompensated cirrhosis:Relationship to short-term risk of severe sepsis,hepatorenal syndrome,and death[J]. Hepatology,2013,58(5):1757-1765.

[17] BRINCH K,MOLLER S,BENDTSEN F,et al. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution,arterial compliance and severity of disease[J]. J Hepatol,2003,39(1):24-31.

[18] FERNANDEZ J,CLARIA J,AMOROS A,et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis[J]. Gastroenterology,2019,157(1):149-162.

[19] ANGELI P,GARCIA-TSAO G,NADIM MK,et al. News in pathophysiology,definition and classification of hepatorenal syndrome:A step beyond the International Club of Ascites(ICA)consensus document[J]. J Hepatol,2019,71(4):811-822.

[20] NARAHARA Y,KANAZAWA H,TAKI Y,et al. Effects of terlipressin on systemic,hepatic and renal hemodynamics in patients with cirrhosis[J]. J Gastroenterol Hepatol,2009,24(11):1791-1797.

[21] SANYAL AJ,BOYER TD,FREDERICK RT,et al. Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs.placebo plus albumin in a pooled analysis of the OT-0401and REVERSE randomised clinical studies[J]. Aliment Pharmacol Ther,2017,45(11):1390-1402.

[22] CAVALLIN M,PIANO S,ROMANO A,et al. Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome:A randomized controlled study[J]. Hepatology,2016,63(3):983-992.

[23] KIM HR,LEE YS,YIM HJ,et al. Severe ischemic bowel necrosis caused by terlipressin during treatment of hepatorenal syndrome[J]. Clin Mol Hepatol,2013,19(4):417-420.

[24] MOORE K,JAMIL K,VERLEGER K,et al. Real-world treatment patterns and outcomes using terlipressin in 203 patients with the hepatorenal syndrome[J]. Aliment Pharmacol Ther,2020,52(2):351-358.

[25] ISRAELSEN M,KRAG A,ALLEGRETTI AS,et al. Terlipressin versus other vasoactive drugs for hepatorenal syndrome[J].Cochrane Database Syst Rev,2017,9:CD011532.

[26] NASSAR JUNIOR AP,FARIAS AQ,D’ALBUQUERQUE LA,et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome:A systematic review and meta-analysis[J]. PLo S One,2014,9(9):e107466.

[27] ARORA V,MAIWALL R,RAJAN V,et al. Terlipressin is superior to noradrenaline in the management of acute kidney injury in acute on chronic liver failure[J]. Hepatology,2020,71(2):600-610.

[28] UTAKO P,EMYOO T,ANOTHAISINTAWEE T,et al. Clinical outcomes after liver transplantation for hepatorenal syndrome:A systematic review and Meta-analysis[J]. Biomed Res Int,2018,2018:5362810.

[29] WONG F,LEUNG W,AL BESHIR M,et al. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation[J]. Liver Transpl,2015,21(3):300-307.

[30] ASSIMAKOPOULOS SF,VAGIANOS CE. Bile duct ligation in rats:A reliable model of hepatorenal syndrome?[J]. World J Gastroenterol,2009,15(1):121-123.

[31] AMAKATA Y,ZHU LM. A rat model of hepatorenal syndrome caused by methoxyflurane:An experimental study[J]. Chin Critical Care Med,1990,4:254.(in Chinese)YOSHIKUNI AMAKATA，朱理珉．甲氧氟烷致鼠肝肾综合征模型的实验研究[J]．危重病急救医学，1990,4:254.

[32] WANG R,LI CM,LI Y,et al. Development of animal models of hepatorenal syndrome[J]. J Shanxi Med Uni,1995,26(4):277-279,361.(in Chinese)王蕊，李春梅，李焰，等．肝肾综合征动物模型的研制[J]．山西医学院学报，1995,26(4):277-279,361.

[33] WANG JB,WANG HT,LI LP,et al. Development of a rat model of D-galactosamine/lipopolysaccharide induced hepatorenal syndrome[J]. World J Gastroenterol,2015,21(34):9927-9935.

[34] SONG W,QI X,ZHANG W,et al. Abnormal expression of urea transporter protein in a rat model of hepatorenal syndrome induced by succinylated gelatin[J]. Med Sci Monit,2015,21:2905-2911.

[35] FORMICA RN,AEDER M,BOYLE G,et al. Simultaneous liverkidney allocation policy:A proposal to optimize appropriate utilization of scarce resources[J]. Am J Transplant,2016,16(3):758-766.

施引文献

资源附件(0)

访问统计